Teva is relaunching its generic contraceptive injection drug Depo-Provera, which is indicated to prevent pregnancy, in the United States.
According to Teva, it is reintroducing the product because it feels the drug brings something to a market lacking options. Teva EVP and president of global generics research and development Dr. Hafrun Fridriksdottir said that this move also "holds significant importance to Teva and our generics R&D priorities.”
Depo-Provera had US sales of about $211 million, according to IMS data as of July 2017.
Read the press release